{
    "nct_id": "NCT04347161",
    "official_title": "Implementation Strategies for Monitoring Adherence in Real Time",
    "inclusion_criteria": "* Adult patient (age > 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.\n* Patient possession of a mobile device that can send/receive SMS texts\n* Ability to respond to questions and engage with \"Penny\" in English\n* Ability to provide informed consent to participate in the study\n* Approval from the patient's medical oncologist to be approached\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to respond to questions and engage with \"Penny\" in English\n* Inability or unwillingness to provide informed consent to participate in the study\n* Inability to engage with SMS text-messaging platform\n* Concurrent enrollment in a therapeutic clinical trial\n* Taking more than one oral targeted therapy or concurrent chemotherapy during the study window\n* Lack of approval from the patient's oncologist",
    "miscellaneous_criteria": ""
}